Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pritumumab in Brain Cancer
NCT04396717Phase 1Completed
- Sponsor
- Nascent Biotech
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pritumumab in brain cancer, sponsored by Nascent Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 24 weeks. Started Feb 2021; status: completed.
02
Drugs
pritumumab
03
Conditions
brain cancer
Beyond the preview
Go deeper on NCT04396717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396717.